论文部分内容阅读
目的:观察并评价艾易舒注射液联合化疗治疗晚期乳腺癌的临床疗效及安全性。方法:选取我院自2004年7月～2006年7月诊断为晚期乳腺癌患者共100例,其中观察组51例,对照组49例;两组均行长春瑞滨加吡柔比星化疗两个疗程,观察组同时使用艾易舒注射液,于化疗第1天及最后1天采血,检查患者血象、肝肾功能及一般情况记录。结果:观察组近期疗效与对照组无明显差异,观察组患者生活质量提高率明显高于对照组,而毒性反应小于对照组。结论:艾易舒注射液联合化疗治疗晚期乳腺癌能够有效提高患者生活质量,减少化疗相关毒性反应。
Objective: To observe and evaluate the clinical efficacy and safety of Ai Yi Shu injection and chemotherapy in the treatment of advanced breast cancer. Methods: A total of 100 cases of advanced breast cancer were diagnosed in our hospital from July 2004 to July 2006, including 51 cases in observation group and 49 cases in control group. Both groups were treated with vinorelbine plus pirarubicin A course of treatment, the observation group also used Yi Yi Shu injection, on the first day and the last day of chemotherapy blood, check the patient’s blood, liver and kidney function and general records. Results: There was no significant difference between the observation group and the control group. The improvement rate of the quality of life in the observation group was significantly higher than that of the control group, but the toxicity was less than that of the control group. Conclusion: Yi Yi Shu injection combined with chemotherapy for advanced breast cancer can effectively improve the quality of life of patients and reduce chemotherapy-related toxic reactions.